Browsing Tag
rare disease mergers
1 post
How Astria Therapeutics’ sale signals a valuation reset for late-stage hereditary angioedema drug assets
Astria Therapeutics’ sale highlights a valuation reset for late-stage rare disease drug assets. Read how this deal reshapes biotech M&A strategy.